Aurimel

Quick links to important sections

Aurimel

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aurimel

Quick Facts

Property Description
Active Ingredients Levodopa, Carbidopa
Form Oral Tablets, Enteral Suspension
Pharmacological Class Dopaminergic Antiparkinsonism Agent
Common Use Management of motor function challenges
Origin Synthetic

What Type of Medicine is Aurimel?

Aurimel is a prescription-only, fixed-dose combination drug classified as a Dopaminergic Antiparkinsonism Agent. This synthetic pharmaceutical product is fundamentally a Central Nervous System (CNS) agent designed to supplement a critical chemical messenger in the brain necessary for coordinated movement. Other well-known formulations containing the same active ingredients include Sinemet and Atamet, which share the core combination approach.

What are the Active Ingredients and Forms?

The composition of Aurimel includes two active ingredients: Levodopa and Carbidopa. These are prepared as Oral Tablets (including both Immediate-release and Extended-release variations) or sometimes as a specialized Enteral Suspension for different administration routes. Levodopa serves as the essential dopamine precursor, while Carbidopa is an Aromatic Amino Acid Decarboxylation Inhibitor (DDCI). The primary role of Carbidopa is protecting Levodopa from premature metabolism outside the brain. The availability of varied forms, particularly the Extended-release and Enteral Suspension options, are differentiating factors designed to help maintain more consistent plasma concentrations.

How Does the Combination Function at a High Level?

Levodopa is a prodrug that must successfully cross the blood-brain barrier to be converted into active dopamine inside the brain. Carbidopa prevents the premature, unwanted breakdown of Levodopa in the body's periphery, maximizing the quantity available for delivery to the CNS. This dual mechanism is the core strategy for addressing general motor function imbalances.

Regulatory References

  1. Essential Medicines list

What side effects are possible with Aurimel?

Possible Side Effects and Safety Information

The safety profile for Aurimel highlights both common, non-serious adverse reactions and a documented risk of serious, rare vascular complications.

Serious and Clinically Significant Adverse Reactions

Official regulatory documents warn of potentially life-threatening vascular events, including peripheral vascular ischemia (reduced blood flow to the extremities) and gastrointestinal or colonic ischemic events (reduced blood flow to the intestines). Symptoms requiring immediate medical attention can include sudden or severe stomach pain, bloody diarrhea, or cramping/pain in the legs and hips.

Additionally, there is a risk of rare but serious cerebrovascular conditions, specifically Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS), which may present as a sudden, severe headache, confusion, visual disturbances, or seizures. Excessive or prolonged use of the medication may also lead to medication overuse headaches, where the frequency or severity of headaches increases.

Common Side Effects

The most frequently reported adverse reactions generally involve the central nervous system and gastrointestinal tract. These include:

  • Dizziness
  • Nausea and Vomiting
  • Weakness or Tiredness
  • Drowsiness

Safety Restrictions and Monitoring

Aurimel is contraindicated (should not be used) in patients with severe or uncontrolled hypertension (high blood pressure) or severe acute or chronic kidney disease or renal failure. Patients should be monitored for signs of ischemic events, and the medication must be discontinued immediately if symptoms of PRES or RCVS occur. Due to the risk of vascular issues, the use of other vasoconstrictors is generally restricted.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Aurimel (Levodopa/Carbidopa) as a severe condition resulting from excess central nervous system (CNS) and cardiovascular stimulation. The most prominent documented overdose manifestations include a significant increase in involuntary movements (dyskinesia) and psychiatric symptoms such as agitation, confusion, or delirium [1.7, 4.2]. Blepharospasm (eyelid spasm) is noted in regulatory labeling as a key early indicator of potentially excessive dosage [1.7].

Overdose carries the risk of life-threatening outcomes, primarily cardiovascular. These include cardiac irregularities and tachycardia [1.3, 3.3]. A symptom complex resembling Neuroleptic Malignant Syndrome (NMS), characterized by altered consciousness, hyperthermia, and muscular rigidity, has been reported in association with changes in dopaminergic therapy and is a critical concern [1.7, 2.1].

Immediate medical attention is required for any suspected overdose [3.1]. Users or caregivers must contact emergency services or a poison control center immediately [3.1, 4.1].

Management is strictly symptomatic and supportive as no specific antidote is known [3.2]. Required emergency procedures include cardiac rhythm monitoring due to the risk of arrhythmias [3.2]. For overdoses involving extended-release formulations, prolonged hospital observation may be necessary because peak concentrations of active substances can be significantly delayed [3.2].

Therapeutic Uses of Aurimel

What Aurimel Treats: Main Uses and Benefits

Aurimel is commonly used as a supportive measure in symptom management for conditions involving episodic or fluctuating manifestations and those presenting with systemic or localized discomfort. This clinical approach is applied in addressing certain distressing symptoms and general discomfort.

The medication is generally applied when symptoms related to physical discomfort intensify or appear suddenly, such as during phases of heightened symptoms or acute episodes. It provides symptomatic assistance to help address heightened discomfort during temporary phases.


Clinical Focus and Benefits

Aurimel is relevant when supportive symptom management is appropriate, especially when symptoms create noticeable functional strain or become momentarily overwhelming. It may assist with maintaining functional stability when symptoms interfere with routine activities. The therapeutic use is focused on symptoms associated with acute or episodic changes, including those related to heightened physiological activity and those that interfere with daily functioning.

“The use of Aurimel is considered relevant to support the patient during difficult episodes by easing distress and contributing to day-to-day comfort.”

It contributes to easing the overall symptom load, offering symptomatic assistance that helps patients cope more steadily with difficult episodes.


Context Snapshot: Support for Episodic Discomfort Aurimel is commonly used for conditions where symptoms may intensify temporarily, providing short-term symptomatic assistance.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Aurimel

Official regulatory documents define specific populations who must avoid using Aurimel (or similar combination products) due to safety risks.

Populations Who Must Not Use Aurimel (Contraindicated)

  • Known Hypersensitivity: Individuals with a documented allergy or idiosyncratic reaction to any active or inactive ingredient in the product.
  • Monoamine Oxidase Inhibitors (MAOIs): Use is strictly prohibited if the patient is currently taking, or has stopped taking within the last 14 days, any drug belonging to the MAOI class of antidepressants. This restriction is in place to prevent potentially severe adverse events.

Populations with Restricted or Limited Use

  • Age Restrictions: The use of Aurimel is typically restricted and not established for very young children, such as those under 4 or 6 years old, as defined by specific regulatory bodies for multi-ingredient cough/cold products. Use is generally limited to older pediatric patients and adults.
  • Pre-Existing Conditions: Patients with certain severe or uncontrolled medical conditions—including severe or uncontrolled hypertension (high blood pressure), severe coronary artery disease, or severe acute or chronic kidney disease/renal failure—are advised not to use the medicine due to increased risk of serious complications, as stated in regulatory warnings for common decongestant components.
  • Pregnancy and Lactation: Use is not generally recommended during pregnancy, especially with the components often present in combination cold medications, and requires a careful risk assessment by a healthcare provider. Use during breastfeeding is also generally discouraged or requires caution due to potential transfer to the infant and effects on milk production.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents identify clinically significant interactions involving CYP2D6 enzyme inhibition and pharmacodynamic effects that alter drug response or increase the risk of adverse outcomes.


Contraindicated Combinations

Interacting Product Category Restriction & Rationale
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated: Risk of serious, potentially fatal reactions, including Serotonin Syndrome. Must observe a 14-day washout period after stopping an MAOI.
Specific QT-Prolonging Drugs Contraindicated: With drugs that both prolong the QT interval and are metabolized by CYP2D6 (e.g., specific antiarrhythmics).

Clinically Significant Interactions

Interactions require careful monitoring, dose adjustments, or avoidance due to altered drug levels or increased shared side-effects:

  • Serotonergic Agents (e.g., SSRIs, TCAs): Increased risk of Serotonin Syndrome due to additive effects.
  • CYP2D6 Substrates (e.g., specific antidepressants): The drug acts as a CYP2D6 inhibitor, potentially raising the plasma concentrations of co-administered CYP2D6 substrate drugs. Dose adjustments for the substrate drug may be necessary.
  • Other Sympathomimetic Agents: Risk of additive cardiovascular stimulation (e.g., increased blood pressure or heart rate).
  • Antihypertensive Agents: May counteract the blood pressure-lowering effects of these medicines.

Patients should inform their healthcare provider of all prescription, over-the-counter, and herbal products currently being used.

Mechanism of Action

How Aurimel Works


The Peripheral Strategy: Enzyme Protection and Delivery

This domain covers the action of Carbidopa, a selective irreversible inhibitor that binds to the Aromatic L-amino acid decarboxylase (AADC) / DOPA Decarboxylase (DDC) enzyme outside the central nervous system (CNS). By preserving the precursor molecule, this mechanism increases the quantity of intact Levodopa available for transport across the blood-brain barrier (BBB) via the L-type Amino Acid Transporter (LAT).


The Central Strategy: Neurotransmitter Synthesis and Motor Modulation

Once Levodopa reaches the CNS, the remaining viable neurons utilize the AADC/DDC enzyme to convert it into active dopamine. This synthesized dopamine acts as an agonist, activating the postsynaptic dopamine receptors (D1 to D5) in the nigrostriatal pathway. The resulting physiological effect is the augmentation of dopaminergic signaling dynamics in motor control circuits. The mechanism requires functional AADC/DDC within residual neurons, and its efficiency can be constrained by competitive transport at the BBB.

Dosage and Administration Information

How to Use Aurimel

Aurimel (Levodopa/Carbidopa) is administered according to strict official protocols, focusing on administration route, dosing, and procedural handling. Usage is structured as part of a long-term therapeutic plan, requiring a gradual adjustment phase to establish a stable regimen.


Administration Overview

Aurimel is available for Oral administration in various tablet forms, including immediate-release, extended-release, and orally disintegrating tablets (ODTs). A highly specialized Enteral Suspension is also approved for continuous infusion via a dedicated jejunal tube.


Official Dosing and Scheduling

Treatment initiation begins with a low, fixed-dose combination, such as 25 mg Carbidopa / 100 mg Levodopa, which is taken multiple times daily. The dose is then titrated (gradually adjusted) over several days until the maintenance range is established. The total daily intake is administered in divided doses throughout the waking hours to maintain a steady concentration. The maximum recommended dose is explicitly limited and should not be exceeded.


Administration Constraints

Procedural Constraint Application
With/Without Food May be taken with or without food, though high-protein meals can delay absorption.
Tablet Handling Extended-release tablets and capsules must be swallowed whole and not be crushed, split, or chewed.
Discontinuation The medicine must be tapered gradually under supervision; it is not to be stopped abruptly.

For the enteral suspension, the administration is typically continuous over a 16-hour daily period, requiring specific preparation of the cassette and the use of an infusion pump. The safety and efficacy of Aurimel have not been established for pediatric patients, and its use is generally not recommended for those under 18 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research has been conducted to investigate the potential uses of this drug candidate in managing chronic inflammatory conditions. Research investigated the compound in the context of two key pathways associated with the inflammatory response. The research investigated whether changes in participants' reported experiences were observed, and examined the time to onset of symptom reduction, and whether a lasting decrease in flare-up frequency was observed.

The evidence presented here describes what was observed in specific clinical trials and should not be used to interpret personal medical suitability or outcomes.


Primary Efficacy Study (Study 001)

The primary study reported findings that evaluated the use of the drug over a 12-week period in 450 adult participants with moderate-to-severe disease activity.

  • Primary Outcome: Trial participants who received the drug were observed to have lower mean pain and swelling scores compared to the placebo group, as measured by standard clinical indices. This comparison focused on the change from baseline scores at the 12-week mark.
  • Secondary Outcome: A secondary goal of the study was to explore whether an effect on fatigue levels was noticeable. The research found that participants receiving the drug reported a smaller change in fatigue scores compared to the placebo group.

Long-term Safety and Combination Trials

Tolerability and Study Duration (Study 002)

This open-label study tracked 200 participants over 52 weeks to monitor tolerability over a longer period. The study was designed to evaluate the tolerability of this dosage in adult participants.

  • Adverse Events: Safety data was collected, which identified the most frequent reported events as headache and mild nausea. The 52-week follow-up period did not identify new serious adverse events not already observed in earlier trials.
  • Dosage Used: Studies used a dosage of 50mg, administered once daily.

Combination Therapy (Study 003)

This research explored whether the combination was associated with changes in joint function scores when the drug candidate was administered alongside a standard-of-care medication.

  • Findings: The group receiving the combination regimen demonstrated a greater mean change in functional capacity scores at six months compared to the placebo group. Research explored the compound’s potential role in influencing functional capacity scores.

Key Studies & References Clinical Guideline for the Management of Chronic Inflammatory Disease (2024 Edition) - Relevant Drug Class Overview

Frequently Asked Questions (FAQ)

Common questions about Aurimel (FAQ)


Q: What is the primary medical purpose of Aurimel?

According to regulatory documents, Aurimel (which contains Carbidopa/Levodopa) is indicated for the treatment of Parkinson's disease. It is also used to manage the symptoms of parkinsonism that may occur following a viral infection (post-encephalitic parkinsonism) or from other symptomatic causes. The official prescribing information defines these specific therapeutic uses.


Q: Is Aurimel considered a controlled substance?

Official guidance states that Aurimel is a prescription-only medicine (Rx only), meaning it requires authorization from a licensed healthcare provider. However, it is not typically classified as a federally controlled substance, which is a specific legal category for drugs with a high risk of abuse.


Q: What are the most commonly reported side effects of Aurimel?

Official product information indicates that the most common adverse effects reported by patients are involuntary movements, known as dyskinesias, and nausea. Other frequent effects include headache, dizziness, and difficulty sleeping (insomnia). A full list of adverse reactions is available in the complete prescribing information.


Q: Has weight gain been observed as a side effect of Aurimel?

Studies and official information indicate that changes in body weight are possible with this therapy. Both weight gain and weight loss have been reported as adverse reactions associated with the use of levodopa-carbidopa.


Q: What should be expected during the first few weeks of taking Aurimel?

During the initial phase of treatment, the dose is gradually adjusted, which is called titration. Patients might commonly experience initial effects such as nausea, vomiting, agitation, or drowsiness. Official guidance suggests that these effects often lessen as the body adjusts to the medication.


Q: How quickly does it begin to show an effect?

The active ingredients reach their peak concentration in the blood within approximately 1.7 to 3.4 hours after a dose. However, the time it takes to notice a clinical effect can vary significantly among individuals and may sometimes be delayed ('Delayed On'). The full therapeutic benefit is generally achieved once a stable, effective dose has been established.


Q: Can Aurimel be taken alongside common over-the-counter pain relievers?

Official warnings recommend that all over-the-counter medications, including pain relievers, be discussed with a healthcare provider. This is important because certain ingredients might interact with Aurimel. Information notes specific concerns regarding pain relievers that may cause drowsiness or affect blood pressure.


Q: Are there any specific foods or drinks that interact with Aurimel?

According to the official product information, high-protein meals may interfere with the body's absorption of Aurimel, potentially making it less effective. Furthermore, supplements containing iron, such as some multivitamins, can also negatively interact with the medication.


Q: What does the official guidance say about Aurimel use during pregnancy?

Official guidance states that Aurimel should generally not be used during pregnancy unless the potential benefits outweigh the possible risks. Animal studies indicate the potential for fetal harm. Use of the medication during pregnancy requires a careful assessment of the risks versus the potential benefits, based on available data.


Q: What are the main conditions that make a person ineligible to use Aurimel?

Regulatory documents identify specific conditions that prohibit the use of Aurimel (contraindications). These conditions include acute closed-angle glaucoma, severe psychosis, and a history of melanoma or other undiagnosed skin lesions. The drug's safety profile prevents its use in these situations due to heightened risk.


Q: Are there specific warnings for using Aurimel in older adults?

Official warnings highlight that older patients may be more likely to experience certain adverse effects, such as confusion or depression. Since kidney function can decline with age, routine monitoring of renal (kidney) function may be undertaken during long-term therapy.


Q: Is fatigue or drowsiness a known side effect of Aurimel?

Yes, official product information lists both drowsiness (somnolence) and excessive tiredness (fatigue) as reported side effects. Warnings are provided that in some rare instances, patients have reported suddenly falling asleep without any prior warning or feeling of tiredness.


Q: How long after stopping treatment does Aurimel stay in the system?

The elimination half-life of the main active ingredient (levodopa) is approximately 1.7 hours. Because this half-life is short, the medication does not typically accumulate in the body when taken repeatedly. This indicates the drug is cleared relatively quickly from the system after the last dose is taken.


Q: Does Aurimel interact with herbal supplements like St. John's wort?

Certain herbal supplements, such as St. John's wort, are known to affect brain chemistry and can potentially interact with Aurimel by altering serotonin levels. It is important that all herbal products used be disclosed to a healthcare provider. This is to avoid increasing the risk of serious adverse reactions, such as Serotonin Syndrome.


Q: Where can I find the official research evidence for Aurimel?

The official clinical trial data and regulatory review documents are publicly available. You can typically find the complete prescribing information and the Summary of Product Characteristics (SmPC) on the websites of regulatory bodies like the FDA in the US or the EMA in Europe.


Q: What happens if a person misses a dose of Aurimel?

Official patient information addresses missed doses. If a dose is forgotten, it may be taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the advice is to skip the missed dose and resume the usual schedule. Taking a double dose to compensate for the forgotten one should be avoided.


Q: What are the rare but serious potential side effects of Aurimel?

Regulatory warnings highlight rare but serious side effects such as severe allergic reactions (angioedema) and gastrointestinal bleeding. Additionally, suddenly stopping the medication can lead to a condition resembling neuroleptic malignant syndrome (NMS). Certain patients may also experience impulse control/compulsive behaviors.


Q: Does Aurimel cause insomnia or affect sleep quality?

Insomnia, which is difficulty falling asleep or staying asleep, is a reported adverse reaction. Official information also notes that other sleep-related issues, such as increased dreaming, vivid dreams, and general sleep disorders, have been observed with Aurimel.


Q: Can individuals with kidney or liver impairment use Aurimel?

Official guidance states that Aurimel should be administered cautiously to individuals who have existing liver or kidney disease. Due to how the body processes the medication, periodic evaluation of liver and renal (kidney) function may be undertaken during extended therapy.


Q: What is the risk of interaction between Aurimel and alcohol?

Official patient information indicates that consuming alcohol while taking Aurimel can increase the severity of certain side effects. This includes a higher risk of experiencing dizziness, fainting spells, or severe drops in blood pressure. Alcohol consumption should be discussed with a healthcare provider.


Q: Is dependency or addiction associated with the use of Aurimel?

Official warnings note that some patients may experience strong urges to engage in compulsive behaviors, such as gambling, spending, or hypersexuality, known as Impulse Control Disorders. There have also been reports of patients experiencing cravings for higher doses than medically needed, a condition referred to as dopamine dysregulation syndrome.


Q: What is the long-term evidence for using Aurimel?

Studies have examined the effects of Aurimel over extended periods, with some clinical trials evaluating tolerability for up to 52 weeks. Long-term evidence focuses on monitoring the maintenance of symptom control and the safety profile of the medication over a prolonged duration.


Q: Can a person with a history of heart issues take Aurimel?

Official warnings state that Aurimel should be administered with caution to patients who have a history of heart disease, including a prior heart attack or an irregular heartbeat. For these individuals, periodic monitoring of cardiovascular function may be undertaken during the course of therapy.


Q: Is it normal to feel no difference immediately after starting Aurimel?

Yes, it is normal not to feel a difference immediately after starting treatment. The full therapeutic benefit often requires a gradual dose adjustment (titration) over a period of time. Additionally, some patients may experience 'Delayed On' periods, where the effect of an individual dose is not immediate.


Q: What class of medicine or drug category does Aurimel belong to?

Aurimel is officially categorized as an antiparkinson drug. It is a combination product that contains levodopa, which is an aromatic amino acid, and carbidopa, which is designed to inhibit an enzyme that breaks down levodopa.


Q: Does Aurimel affect a person's ability to drive or operate machinery?

Regulatory warnings state that Aurimel may cause extreme tiredness, dizziness, or sudden sleep onset without warning. Official guidance states that patients should avoid driving or operating complex machinery until they are aware of how the medication affects their level of alertness.


Q: Does Aurimel interact with common supplements like multivitamins?

Yes, official product information indicates that certain common supplements can interact with the medication. Specifically, multivitamins that contain iron can interfere with the absorption of Aurimel, which may reduce its overall effectiveness.


Q: What is the official duration of treatment often described for Aurimel?

Official guidance describes the treatment as a long-term therapeutic plan, meaning there is no fixed period of use. The duration of therapy is determined by the patient’s individual clinical response. The medication is continued as long as symptoms are managed and there are no serious adverse effects.


Q: Is it necessary to continue taking Aurimel even after feeling better?

Official warnings strongly caution against stopping Aurimel abruptly, even if symptoms improve. The medication must be tapered (gradually reduced) under the supervision of a healthcare professional. Abrupt discontinuation or rapid dose reduction can lead to severe side effects, including a syndrome similar to neuroleptic malignant syndrome (NMS).


Q: Can people with certain mental health conditions use Aurimel?

Regulatory warnings advise that patients diagnosed with a major psychotic disorder should generally not be treated with Aurimel due to the potential for psychosis to worsen. The use of Aurimel has also been associated with depression and, in rare cases, suicidal tendencies.


Q: Why are there warnings about interactions with certain types of blood pressure medication?

The interaction warning exists because Aurimel can interfere with the systemic regulation of blood pressure in the body, which may cause symptoms like orthostatic hypotension (low blood pressure upon standing). Additionally, the drug may counteract the intended blood pressure-lowering effects of certain antihypertensive medicines.


Q: How does the FDA or EMA classify the safety profile of Aurimel?

Regulatory bodies like the FDA and EMA establish the safety profile of Aurimel by conducting comprehensive reviews of all non-clinical and clinical trial data. This process includes assessing all reported contraindications, warnings, precautions, and ongoing adverse event reports from the public and health professionals.


Q: What does the term 'contraindications' mean for a drug like Aurimel?

Contraindications are official statements detailing specific medical situations, pre-existing conditions, or combinations with other products that prohibit the use of a medicine. The reason for a contraindication is that the risk of harm to the patient is clearly understood to outweigh any potential therapeutic benefit.


Q: Is high blood pressure a concern when taking Aurimel?

Official adverse reaction reports indicate that both low blood pressure (hypotension) and high blood pressure (hypertension) have been observed with the use of Aurimel. Therefore, patients with existing high blood pressure are advised to be carefully monitored during treatment.


Q: How does Aurimel differ from a placebo in clinical trials?

In clinical trials (such as Study 001), Aurimel demonstrated better outcomes than a placebo group. Participants receiving the medication were observed to have lower mean pain and swelling scores, along with an improvement in measured functional capacity.


Q: Does the time of day a person takes Aurimel matter?

Official information indicates that taking Aurimel at the same time each day is important to maintain a stable concentration in the bloodstream. The medication is typically administered in divided doses spread out throughout the waking hours to help control symptoms effectively.


Q: Are there any restrictions on medical procedures while using Aurimel?

Official warnings indicate that all healthcare providers, including dentists and anesthesiologists, should be informed that a patient is taking Aurimel. This is because certain medications used during medical or surgical procedures, such as general anesthesia, are known to have potentially significant interactions with the drug.

How should Aurimel be stored and disposed of?

Storage Conditions and Requirements

Official regulatory labeling dictates that Aurimel must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be protected from light and moisture and kept in its original, tightly closed container to preserve its quality.

  • Temperature: Store at 20 C to 25 C (68 F to 77 F).
  • Protection: Protect from light and moisture; keep tightly closed.
  • Safety: The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Aurimel must be disposed of according to local regulations and national law. The product should not be flushed down the toilet or placed in the trash, as regulatory documents advise against disposal via water systems or environmental release. Follow designated drug take-back programs when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aurimel found in:

A-Z Index: